CRYPTOME GETS OPTION FOR ANTI-INFLAMMATORY DRUG LICENSE.Cryptome Pharmaceuticals Ltd, Melbourne, Australia, (ASX ASX See: Australian Stock Exchange :CRP C-reactive protein (CRP) A protein present in blood serum in various abnormal states, like inflammation. Mentioned in: Pelvic Inflammatory Disease CRP, n.pr See C-reactive protein. ) has signed an agreement with the University of Virginia giving the company sole option to an exclusive license over a novel class of protein-derived compounds with potent anti-inflammatory action. Upon the exercise of the option and finalizing terms, the agreement gives Cryptome an exclusive license for the USA, the world's largest pharmaceutical market. Cryptome has up to 12 months to exercise the option, but is intending to begin work on the molecule under an MTA (1) (Message Transfer Agent or Mail Transfer Agent) The store and forward part of a messaging system. See messaging system. (2) See M Technology Association. 1. (messaging) MTA - Message Transfer Agent. (material transfer agreement) in the immediate future. The lead protein-derived drug-candidate (CR014) prevents 'vascular leak' or the leakage of fluid through blood vessel blood vessel n. An elastic tubular channel, such as an artery, a vein, a sinus, or a capillary, through which the blood circulates. blood vessel(s), n the network of muscular tubes that carry blood. walls, which is an essential part of the inflammatory reaction. Vascular leak contributes to morbidity and mortality Morbidity and Mortality can refer to:
Adult respiratory distress syndrome (ARDS), also called acute respiratory distress syndrome, is a type of lung (pulmonary) failure that may result from any disease that causes large amounts of fluid to (ARDS Ards District (pop., 2001: 73,244), Northern Ireland. Formerly part of County Down, Ards was established as a district in 1973. Much of its land is devoted to crops and pasture. Newtownards, settled c. 1608 by Scots, is its administrative seat and manufacturing centre. ), multiple sclerosis, trauma, strokes and heart attacks. The commercial outlook for CR014 is attractive because there are at present no effective therapies for vascular leak on the market, and CR014 works by a mechanism distinct from those of other companies pursuing this major unmet need. CR014 has shown in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. that it can prevent vascular leak caused by clinically relevant inflammatory stimulus such as Tumor necrosis factor tumor necrosis factor n. Abbr. TNF A protein that is produced in the presence of an endotoxin, especially by monocytes and macrophages, is able to attack and destroy tumor cells, and exacerbates chronic inflammatory diseases. , as well as agents involved in thrombosis (thrombin thrombin: see blood clotting. ) and allergies (histamine). In addition, CR014 has in vivo efficacy and potency in a mouse-model of ARDS. A single injection of CR014 prevented the major pathological hallmarks of ARDS: leakage of plasma into the lung as well as the cellular infiltrate that accompanies this disease. ARDS is a life-threatening condition of breathing failure caused by severe fluid build-up in the lungs, and it is a frequent cause of mortality in intensive care units. The syndrome affects over 150,000 people in the United States every year. The addition of CR014 to its development pipeline will give Cryptome two drug candidates in the inflammation/cardiovascular field, both of which have shown promising activity in preclinical testing in animal models. Its lead product, CR001, has shown promise in animal studies as an anti-thrombosis treatment and pre-clinical disease testing of CR014 is expected to be fast tracked for ARDS and neurological indications. Dr Vic Ilag, Cryptome's chief scientific officer commented: "We are delighted to be able to acquire CR014, as not only does it have wide ranging clinical potential but it is also an excellent fit for Cryptome being based on a fragment of a protein and having efficacy in one of our primary disease focus areas of inflammatory/cardiovascular disease. It immediately strengthens our development pipeline and our scientific and clinical expertise in the area will ensure that its clinical development is expedited." Professor Mathew Vadas, Cryptome's acting CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. said "Cryptome's mission of discovering and bringing protein based drugs to IND status for diseases with significant market potential will be significantly supported by this acquisition." He added, "With an ever growing innovation gap in big Pharma's pipeline, Cryptome is poised to make a valuable contribution to filling this need with a growing list of novel products." The discoverer of CR014, Professor Martin Schwartz, an acknowledged leader in the field of vascular biology, has accepted Cryptome's invitation to join the company as a scientific advisor. Prof. Schwarz noted, "Cryptome will be the perfect home for CR014. It is a good match for the type of drugs Cryptome seeks to develop and Cryptome has the essential clinical and scientific expertise to make rapid progress in bringing CR014 to the market quickly. I'm delighted that I'll be able to continue to contribute to its development through my role as a scientific advisor to the company." About Cryptome Pharmaceuticals Cryptome Pharmaceuticals Ltd is a globally-linked, Melbourne-based biotechnology company created to discover and develop effective and safe protein-derived medicines targeting cancer, cardiovascular disease and neuroinflammatory conditions, using a proprietary proteomics-based technology platform. Cryptome exploits evolution for accelerated drug discovery. For information, visit http://www.cryptomepharmaceuticals.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion